Browse online courses and resources available for Continuing Medical Education Credit.

CME Courses
Collapse Advancing the Care of Patients with SCLC: Emerging Treatment Options

Access Course

 

Emerging Opportunities for Immunotherapy in Small Cell Lung CancerDr Charles Rudin discusses the latest data on the use of checkpoint inhibition in patients with SCLC.

 

This activity is intended for oncologists, pulmonologists, and pathologists.

 

The goal of this activity is to review the latest advances in the use of immune checkpoint inhibition in patients with small cell lung cancer (SCLC).

 

 

 

 

 

 

Approximate Time to Complete: 15 minutes

 

Credit Available: Dec. 18, 2018- Dec. 18, 2019

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Original Course Date: December 18, 2018

Approved Credit:
  • ABIM: 0.25 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.25 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Advancing the Care of Patients with SCLC: Emerging Treatment Options
    Collapse Case Studies in Clinical Decision Making in mCRC

    Access Course

     

    The use and challenges of immunotherapy in patients with MSI-H CRC is explored through 2 cases.

     

    This activity is intended for oncologists, gastroenterologists, surgeons, nurses, pharmacists, and other healthcare professionals who treat patients with colorectal cancer (CRC).

     

    The goal of this activity is to examine the management of microsatellite instability-high (MSI-H) CRC, including testing and treatment with immunotherapy.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 18, 2018 - Dec. 18, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 18, 2018

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ACPE: 1 hour CEU
  • ANCC: 1 hour Contact Hour

  • MORE INFOMORE INFO Case Studies in Clinical Decision Making in mCRC
    Collapse Cases in mRCC: Steps to Optimizing Care

    Access Course

    Cases in mRCC: Steps to Optimize CareDr Monty Pal explores the role of immunotherapy in 2 patients with advanced renal cell carcinoma (RCC).

     

    This activity is intended for oncologists, urologists, nephrologists, nurses, pharmacists, and other healthcare professionals who manage patients with renal cell carcinoma (RCC).

     

    The goal of this activity is to evaluate the latest understanding of the role of immunotherapy in patients with advanced RCC.

     

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: December 19, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 19, 2018

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ACPE: 1 hour CEU
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ANCC: 1 hour Contact Hour

  • MORE INFOMORE INFO Cases in mRCC: Steps to Optimizing Care
    Collapse Challenges and Opportunities: Steps to Maximizing Cancer Immunotherapy Regimens

    Access Course

     

    Experts discuss the latest research in the use of cancer immunotherapies.

     

    This activity is intended for oncologists, pathologists, dermatologists, and other healthcare professionals who manage patients with cancer.

     

    The goal of this activity is to discuss emerging strategies in the use of immunotherapy for cancer treatment.

     

     

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 19, 2018- Dec. 19, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 19, 2018

    Approved Credit:
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Challenges and Opportunities: Steps to Maximizing Cancer Immunotherapy Regimens
    Collapse Checkpoint Inhibitors: Managing Immune-Mediated Side Effects

    Access Course

     

    890963.jpg?interpolation=lanczos-none&resize=300:*Follow the cases of 2 patients who developed immune-related adverse events following treatment with immune checkpoint blockade.

     

    This activity is intended for oncologists, emergency medicine physicians, pulmonologists, and nurses.

     

    The goal of this activity is to review strategies for identifying and managing adverse events associated with treatment with immune checkpoint blockade.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Feb. 28, 2018 - Feb. 28, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 28, 2018

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Checkpoint Inhibitors: Managing Immune-Mediated Side Effects
    Collapse Debates and Dilemmas, Part 1: When to Use Immune Checkpoint Inhibitors in Advanced NSCLC and in Whom

    Access Course

     

    Debates and Dilemmas, Part 1: When to Use Immune Checkpoint Inhibitors in Advanced NSCLC and in WhomExperts discuss two cases on first-line management of advanced non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs).

     

    This activity is intended for hematologists/oncologists, pulmonologists, pathologists, and nurses. 

     

     

     

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 26, 2018- Nov. 26, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 26, 2018

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Debates and Dilemmas, Part 1: When to Use Immune Checkpoint Inhibitors in Advanced NSCLC and in Whom
    Collapse Emerging Considerations in the Use of Immune Checkpoint Inhibitors: HCC

    Access Course

     

    892102.jpg?interpolation=lanczos-none&resize=300:*Drs Greten and El-Khoueiry discuss the emergence of checkpoint inhibition therapy in the treatment of advanced HCC.

     

    This activity is intended for oncologists, gastroenterologists, surgeons, and nurses.
     

    The goal of this activity is to review the latest data on the efficacy and safety of immune checkpoint inhibitors in the management of patients with advanced hepatocellular carcinoma (HCC).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Mar. 09, 2018 - Mar. 09, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: March 09, 2018

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Emerging Considerations in the Use of Immune Checkpoint Inhibitors: HCC
    Collapse Emerging Opportunities for Immunotherapy in Small Cell Lung Cancer

    Access Course

     

    Emerging Opportunities for Immunotherapy in Small Cell Lung CancerDr Charles Rudin discusses the latest data on the use of checkpoint inhibition in patients with SCLC.

     

    This activity is intended for oncologists, pulmonologists, and pathologists.

     

    The goal of this activity is to review the latest advances in the use of immune checkpoint inhibition in patients with small cell lung cancer (SCLC).

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Credit Available: Dec. 18, 2018- Dec. 18, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 18, 2018

    Approved Credit:
  • ABIM: 0.25 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.25 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Emerging Opportunities for Immunotherapy in Small Cell Lung Cancer
    Collapse From Adjuvant to Metastatic in Melanoma: What Should You Know?

    Access Course

     

    From Adjuvant to Metastatic in Melanoma: What Should You Know?Experts discuss the role of immunotherapy in the treatment of patients with melanoma across the disease settings.

     

    This activity is intended for oncologists, dermatologists, pathologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

     

    The goal of this activity is to discuss the evolving role for immunotherapy in the treatment of patients with melanoma.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 24, 2018 - Dec. 24, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 17, 2017

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour
  • ACPE: 0.50 hours CEU

  • MORE INFOMORE INFO From Adjuvant to Metastatic in Melanoma: What Should You Know?
    Collapse Immune Checkpoint Inhibitors in Lung Cancer: No Longer The Road Less Traveled?

    Access Course

     

    Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Experts discuss emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers.

     

    This activity is intended for  oncologists, pulmonologists, and pathologists.

     

    The goal of this activity is to discuss how to integrate emerging clinical trial data on the use of immune checkpoint inhibitors into the management of patients with advanced lung cancers.

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 9, 2018- Nov. 9, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 09, 2018

    Approved Credit:
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Immune Checkpoint Inhibitors in Lung Cancer: No Longer The Road Less Traveled?
    Collapse Introduction to Immunology – <i>Second Edition</i>

    This interactive course provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy. 

    intro_to_immunology_second_edition_screenshot_2.png

    Credit Available: September 28, 2018- September 29, 2018

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. (as of Aug. 21, 2018). 

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

    Educational Objectives
    After completing this activity, the participant should be better able to:

    • Describe the function of the components of the immune system, including relevant cells, molecules and organs of the immune system.
    • Differentiate between the adaptive immune system and the innate immune system.
    • Recognize the barriers to effective immunotherapy, including mechanisms by which tumors locally disable and/or evade the immune system. 

     

    Faculty
    Christian M. Capitini, MD
    Assistant Professor
    University of Wisconsin Carbone Cancer Center
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-18-400-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.  Designated for 0.5 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Christian Capitini, MD: Consulting Fees at Nektar Therapeutics

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period September 28, 2018 through September 28, 2019 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Introduction to Immunology – Second Edition.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: September 28, 2018

    Approved Credit:
  • ACPE: 1 hour CEU
  • ANCC: 1 hour Contact Hour
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Introduction to Immunology – <i>Second Edition</i>
    Collapse Novel Concepts in the Management of RCC

    Access Course

     

    900287.jpg?interpolation=lanczos-none&resize=300:*Drs Rini and McDermott discuss the latest approvals and ongoing research into immunotherapy for advanced RCC.
     

    This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with RCC.

     

    The goal of this activity is to discuss the evolving role of cancer immunotherapy in renal cell carcinoma (RCC).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 19, 2018- Sep. 19, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 19, 2018
    MORE INFOMORE INFO Novel Concepts in the Management of RCC
    Collapse Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer

    Access Course

     

    902370.jpg?interpolation=lanczos-none&resize=300:*Drs Milowsky and Smith discuss the evolving use of checkpoint inhibition in patients with advanced bladder cancer.

     

    This activity is intended for oncologists, urologists, nurses, and other healthcare professionals who treat patients with bladder cancer.

     

    The goal of this activity is to discuss the most up-to-date use of immunotherapy in the treatment of patients with advanced bladder cancer.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 27, 2018- Sep. 27, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 27, 2018

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer
    Collapse Practice Your Skills: Managing Patients with Advanced NSCLC

    Access Course

     

    Practice Your Skills: Managing Patients With Advanced NSCLCApply best practices to assess, treat, and educate patients with advanced NSCLC.

     

    This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.

     

    The goal of this activity is to build physician confidence in identifying and ordering appropriate evidence-based treatment regimens and providing patient education.

     

     

     

     

     

     

    Approximate Time to Complete: 1 hour

     

    Credit Available: Dec. 13, 2018- Dec. 13, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 13, 2018

    Approved Credit:
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Practice Your Skills: Managing Patients with Advanced NSCLC
    Collapse The Evolving Role of Immunotherapy in NSCLC: Pearls for Clinical Practice

    Access Course

     

    890347.jpg?interpolation=lanczos-none&resize=300:*Faculty discuss recent and ongoing clinical trials that affect clinical decisions with the use of immunotherapy in NSCLC.


    This activity is intended for hematology/oncology specialists and pharmacists.
     

    The goal of this activity is to improve knowledge of clinical trial designs and practical application of data in order to improve management of patients with non-small cell lung cancer (NSCLC).

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Feb. 27, 2018 - Feb. 27, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 27, 2018

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)
  • ACPE: 0.50 hours CEU
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO The Evolving Role of Immunotherapy in NSCLC: Pearls for Clinical Practice
    Collapse The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer

    Access Course

     

    902337.jpg?interpolation=lanczos-none&resize=300:*Learn about current and emerging immunotherapy options and how to monitor for and manage immune-related adverse events.


    This activity is intended for nurses and nurse practitioners.

     

    The goal of this activity is to provide perspective on where immune checkpoint inhibitors fit into treatment paradigms, as well as on monitoring and management strategies for immune-related adverse events (irAEs).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 26, 2018- Sep. 26, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 26, 2018

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour
  • ABIM: 1 hour CEU

  • MORE INFOMORE INFO The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer